التفاصيل البيبلوغرافية
| العنوان: |
Effects of high‐dose versus standard‐dose quadrivalent influenza vaccine among patients with diabetes: A post‐hoc analysis of the DANFLU‐1 trial |
| المؤلفون: |
Lassen, Mats C. Højbjerg, Johansen, Niklas Dyrby, Modin, Daniel, Nealon, Joshua, Samson, Sandrine, Dufournet, Marine, Loiacono, Matthew M., Larsen, Carsten Schade, Jensen, Anne Marie Reimer, Landler, Nino Emanuel, Claggett, Brian L., Solomon, Scott D., Landray, Martin J., Gislason, Gunnar H., Køber, Lars, Jensen, Jens Ulrik Stæhr, Sivapalan, Pradeesh, Vestergaard, Lasse Skafte, Krause, Tyra Grove, Biering‐Sørensen, Tor |
| المساهمون: |
Sanofi |
| المصدر: |
Diabetes, Obesity and Metabolism ; volume 26, issue 5, page 1821-1829 ; ISSN 1462-8902 1463-1326 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2024 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Aim High‐dose quadrivalent influenza vaccine (QIV‐HD) has been shown to be more effective than standard‐dose (QIV‐SD) in reducing influenza infection, but whether diabetes status affects relative vaccine effectiveness (rVE) is unknown. We aimed to assess rVE on change in glycated haemoglobin [HbA1c (∆HbA1c)], incident diabetes, total all‐cause hospitalizations (first + recurrent), and a composite of all‐cause mortality and hospitalization for pneumonia or influenza. Methods DANFLU‐1 was a pragmatic, open‐label trial randomizing adults (65‐79 years) 1:1 to QIV‐HD or QIV‐SD during the 2021/22 influenza season. Cox proportional hazards regression was used to estimate rVE against incident diabetes and the composite endpoint, negative binomial regression to estimate rVE against all‐cause hospitalizations, and ANCOVA when assessing rVE against ∆HbA1c. Results Of the 12 477 participants, 1162 (9.3%) had diabetes at baseline. QIV‐HD, compared with QIV‐SD, was associated with a reduction in the rate of all‐cause hospitalizations irrespective of diabetes [overall: 647 vs. 742 events, incidence rate ratio (IRR): 0.87, 95% CI (0.76‐0.99); diabetes: 93 vs. 118 events, IRR: 0.80, 95% CI (0.55‐1.15); without diabetes: 554 vs. 624 events, IRR: 0.88, 95% CI (0.76‐1.01), p interaction = 0.62]. Among those with diabetes, QIV‐HD was associated with a lower risk of the composite outcome [2 vs. 11 events, HR: 0.18, 95% CI (0.04‐0.83)] but had no effect on ∆HbA1c; QIV‐HD adjusted mean difference: ∆ + 0.2 mmol/mol, 95% CI (−0.9 to 1.2). QIV‐HD did not affect the risk of incident diabetes [HR 1.18, 95% CI (0.94‐1.47)]. Conclusions In this post‐hoc analysis, QIV‐HD versus QIV‐SD was associated with an increased rVE against the composite of all‐cause death and hospitalization for pneumonia/influenza, and the all‐cause hospitalization rate irrespective of diabetes status. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1111/dom.15498 |
| الإتاحة: |
https://doi.org/10.1111/dom.15498Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.3D45947F |
| قاعدة البيانات: |
BASE |
